AI-generated analysis. Always verify with the original filing.
Operating Income was -$9.0M (49.6%) Net Income was -$8.8M (49.5%) Eps was $-0.78 (54.7%) Free Cash Flow was -$8.2M
Key Takeaways
1Operating loss narrowed 49.6% to -$9.0M, primarily driven by the winding down of clinical study costs for drug candidates and reductions in employee-related expenses.
2Net loss improved 49.5% to -$8.8M, reflecting reduced clinical trial activity and lower general administrative expenses including insurance and compensation.
3Diluted EPS improved 55% to -$0.78, benefiting from the reduced net loss despite an increased share count from equity raises.
4Net cash used in operating activities decreased 50% to -$8.2M, compared to -$16.5M in the prior year, aligning cash consumption with the reduced operational scope.
5The company continues to incur losses and acknowledges that achieving profitability is dependent on successful development and commercialization of product candidates.
Operating Performance and Cost Reduction
Earnings and Per-Share Results
Cash Flow and Liquidity Position
Net cash used in operating activities was -$8.2M for the year ended December 31, 2025, a significant improvement from -$16.5M in the prior year. This 50% reduction in operating cash burn corresponds directly to the reduced clinical trial spending. Capital expenditures remained minimal at $12,000, resulting in free cash flow of approximately -$8.2M. Net cash provided by financing activities resulted from capital raises through the sale of equity, which management noted was critical for near-term liquidity.